Molly Gibson, PhD, has focused her attention on building companies at the intersection of AI and life sciences for the past decade, having co-founded both Generate: Biomedicines and Lila Sciences.

Covalent inhibitors represent a class of small molecules that form irreversible or quasi‐irreversible bonds with their protein targets, offering enhanced potency, prolonged duration of action and the ...